• / Free eNewsletters & Magazine
  • / My Account
Home>Search Results

Related Content

  1. Videos
  2. Articles
  1. Generic Biologics Face Uphill Battle

    Morningstar generic-pharmaceuticals analyst Brian Laegeler discusses the outlook for generic biologics in the U.S. given a strong branded-drug lobby and complex manufacturing processes.

  2. Will 'Knockout' Mice Make a Knockout Stock?

    After a strong runup from our recommendation, is it time to take money off the table in Lexicon Pharmaceuticals?

  3. Going Global to Ease Drug Trial Process

    Contract research organization Parexel is exploiting its global footprint to rapidly enroll patients in drug studies.

  4. Will a Medco/Express Scripts Merger Pass Regulatory Muster?

    Shareholders would be well-served by the pharmacy benefit managers' merger, but regulators are unlikely to sign off on it, says Morningstar's Matt Coffina.

  1. Schwab, Piper Jaffray Expand Access to Munis

    Charles Schwab announced Monday that it has joined with Piper Jaffray to provide clients access to Piper Jaffray's new issue municipal bonds through Schwab's BondSource Platform.

  2. Top Portfolio Products: Schwab, Piper Jaffray to Boost Muni Bond Access

    New products introduced over the last week include an arrangement between Schwab and Piper Jaffray to provide investors greater access to the latter’s new muni bonds; more.

  3. Schwab connects with Piper Jaffray on muni bonds

    Deal expands universe of issues available to Schwab clients via BondSource.

  4. Piper Jaffray Companies, Inc. PJC Q3 2011 Earnings Call Transcript

    Good morning, ladies and gentlemen, and welcome to the Piper Jaffray Companies conference call to discuss the financial results for the third quarter of 2011.

1
ShareEmail
Print
Text Size
Comment
blog comments powered by Disqus
Our Products
Tools
Resources
Services
Upcoming Events
Conferences
Webinars

©2012 Morningstar Advisor. All right reserved.